3 results
Approved WMOCompleted
Primary:The primary objective of Study 218MS305 is to determine whether prolonged-release fampridine (10 mg BID) has a clinically meaningful effect on patient-reported walking ability over a 24-week study period.Secondary:The secondary objectives…
Approved WMOWill not start
Primary Objective: The primary objective of this randomized controlled study is to assess the safety and efficacy of the VITARIA* System when added to stable, guideline-directed medical therapy for patients with heart failure and reduced left…
Approved WMORecruiting
To determine the minimum number of CESB-guided tissue samples needed to establish a final histopathological biopsy diagnosis for ROLs.